Golimumab (Simponi®) is a human IgG1 monoclonal antibody and binds with high affinity and specificity to both soluble and transmembrane forms of TNFa, which prevents the binding of TNFa to its receptors, thereby neutralizing its biological activity. It is used among others for the treatment of Rheumatoid arthritis and Psoriatic arthritis.


PPS has generated considerable experience in the analysis of different originator batches as well as variants of biosimilars of Golimumab.


We have established an analytical program according to the ICH Q6B guidance, including the method setup, validation of customer specific methods and release testing.

This package includes different assays for protein quantification and characterizing the protein primary structure and secondary structure, as well as detailed analysis of N-glycosylation and protein modification, including the detailed look for the C-terminal lysine heterogeneity on the heavy chain.

 

Your contact for Golimumab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100
Email: salesproteinservices@ProtagenProteinServices.com